Title:
NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells

Authors and affiliations:
Kai Lee Yap 1, Stephanie I. Fraley 2, Michelle M. Thiaville 3#, Natini Jinawath 3*, Kentaro Nakayama 4, Jianlong Wang 5, Tian-Li Wang 6, Denis Wirtz 2, Ie-Ming Shih 7.

1 Johns Hopkins University, Department of Pathology, Pathobiology Graduate Program, Baltimore, MD 21231, USA
2 Johns Hopkins University, Department of Chemical and Biomolecular Engineering and Physical Sciences - Oncology Center, Baltimore, MD 21218, USA
3 Johns Hopkins Medical Institutions, Department of Pathology, Baltimore, MD 21231, USA
4 Shimane University, School of Medicine, Department of Obstetrics and Gynecology, Izumo 693-8501, Japan
5 Mt Sinai Medical Center, Developmental and Regenerative Biology, New York, NY 10029, USA
6 Johns Hopkins Medical Institutions, Departments of Gynecology/Obstetrics and Oncology, Baltimore, MD 21231, USA
7 Johns Hopkins Medical Institutions, Departments of Pathology, Gynecology/Obstetrics and Oncology, Baltimore, MD 21231, USA
#Current address: Louisiana State University, Department of Biological Sciences, Baton Rouge, LA 70803, USA
*Current address: Ramathibodi Hospital, Institute of Computational Bioscience, Mahidol University, Bangkok, Thailand 10400

Running title: NAC1-dependent cytokinesis of cancer cells
Key words: actin/cytokinesis/NAC1/profilin-1

Corresponding author:
Ie-Ming Shih, M.D., Ph.D.
Department of Pathology
Johns Hopkins University
School of Medicine
1550 Orleans Street
CRB-II, Room 305
Baltimore, MD 21231
Phone: 410-502-7774
Fax: 410-502-7943
Email address: ishih@jhmi.edu

The authors declare no conflict of interest

Word count: 4,535
Total number of figures: 7
Abstract

NAC1 is a transcriptional co-repressor protein that is essential to sustain cancer cell proliferation and migration. However, the underlying molecular mechanisms of NAC1 function in cancer cells remain unknown. In this study, we show that NAC1 functions as an actin monomer binding protein. The conserved BTB protein interaction domain in NAC1 is the minimal region for actin binding. Disrupting NAC1 complex function by dominant negative or siRNA strategies reduced cell retraction and abscission during late stage cytokinesis, causing multinucleation in cancer cells. In Nac1-deficient murine fibroblasts, restoring NAC1 expression was sufficient to partially avert multinucleation. We found that siRNA-mediated silencing of the actin binding protein profilin-1 in cancer cells caused a similar multinucleation phenotype and that NAC1 modulated the binding of actin to profilin-1. Taken together, our results indicate that the NAC1/actin/profilin-1 complex is crucial for cancer cell cytokinesis, with a variety of important biological and clinical implications.
Introduction

The Bric-a-Brac Tramtrack Broad complex (BTB) family of proteins shares a conserved BTB protein-protein interaction domain (1, 2) that is present in many DNA and actin binding proteins (3). Nucleus accumbens-associated 1 (NAC1) encoded by NACC1 is a member of the family, and the gene was first identified by the observation that the level of NAC1 transcript was elevated in the rat nucleus accumbens in response to cocaine administration (4). Subsequently, NAC1 has been shown to participate in diverse biological functions ranging from maintenance of stemness and proliferation of embryonic stem cells (5, 6) to the pathogenesis of human cancer (7-12). Like other members of the BTB family, the homodimeric or heterodimeric interaction mediated by its BTB domain is thought to be essential for the various functional activities of NAC1 (7).

The biological role of NAC1 in cancer has recently emerged, as NAC1 has been found to be overexpressed in several types of human cancer including ovarian high-grade serous carcinoma, one of the most lethal neoplastic diseases in women (7, 8, 12-15). One of the mechanisms underlying NAC1 overexpression in ovarian cancer is amplification of the NAC1-encoded gene, NACC1, and analysis of The Cancer Genome Atlas (TCGA) data set demonstrates NACC1 as one of the top potential “driver” genes, showing the highest correlation between DNA and RNA copy number in ovarian high-grade serous carcinomas (11). Moreover, NAC1 upregulation is associated with disease aggressiveness and contributes to the development of chemoresistance (9, 10, 16). NAC1 is essential for survival and growth of ovarian cancer cells that overexpress NAC1, because NAC1-silencing or inactivation through ectopic expression of a deletion mutant containing only...
the BTB domain significantly reduced proliferation of ovarian cancer cells (7-10).

Molecular mechanisms underlying the essential role of NAC1 in cancer cell survival are thought to involve multiple pathways including activation of the Gadd45 cell survival pathway (8, 9), fatty acid metabolism (17), and the HMGB-1 (High-mobility group protein B1) mediated autophagic response (16).

In addition, the possibility that NAC1 is also involved in non-nuclear functions is indicated by the dynamic changes in subcellular localization of NAC1 at different phases of cell cycle progression (18). In non-mitotic cells, NAC1 accumulated in distinct nuclear punctate bodies, which were dissolved into a diffuse pattern of distribution in the cytoplasm during mitosis. NAC1 nuclear bodies immediately reappeared on completion of mitosis (18), suggesting that NAC1 plays a role specifically during cell division. In this study we sought to investigate the role of NAC1 in cell division and to identify molecular mechanisms by which it contributes to the survival of tumor cells. Our results demonstrate that NAC1 is an actin monomer binding protein that regulates actin assembly in cancer cells during cytokinesis, a finding that provides a new perspective on the regulation of this fundamental biological process in tumor cells.

Materials and Methods

Traction force microscopy

The method for embedding 0.1 μm RFP (red fluorescent protein) methoxy fluorescent beads in the polymerized acrylamide substrate (0.1% methylene-bis-acrylamide and 5% acrylamide) was detailed in a previous report (19) and carried out on a glass bottom cell culture dish. A collagen layer was overlaid before SKOV3 N130 tTA cells were seeded
in the dish at a suitable density for time-lapse imaging. An image frame was collected once every 10 minutes to minimize the deleterious effects related to the excitation beam, and to construct time-lapse videos for frame-by-frame measurements of the displacement of the beads. Photomicrographs were taken at 40x magnification to ensure sufficient resolution for resolving miniscule bead displacement using the ‘Tracking’ function in the Nikon Elements software. A total of 80 beads were tracked over the 3 conditions. The comparison of traction generated by the cells was accomplished by measuring maximal displacement of beads from origin along the $x$ and $y$ axis over time and plotting the data as a distribution.

**Measurement of the contractile ring diameter**

N130-induced and non-induced cells were fixed and stained for actin and DAPI. Dividing cells were randomly selected ($n=20$ for each condition) and the diameter of their contractile ring was directly measured using the ImageJ software (National Institutes of Health, Bethesda, Maryland).

**Plotting of cell displacement trajectories**

SKOV3 and HeLa cells seeded in collagen-coated plates were imaged at low magnification every 10 minutes overnight. Using the image recognition software (Metamorph/Metavue) to accomplish tracking of the displacement of individual cells, the $x$ and $y$ coordinates of each cell on each frame were recorded. Stage drift of the moving stage microscope was accounted for in the calculations. Trajectories of individual cells after lentiviral shRNA treatments were plotted after Day 3 and Day 6.
Establishment of primary cell cultures

To establish a primary culture of mouse lung fibroblast in the NAC1 knockout genotype, lung tissue specimens were minced, digested using collagenase (10 μg/ml) at 37°C on a rotisserie rotator, and sieved to isolate single cells. Cells were cultured in RPMI 1640 supplemented with 10% (v/v) FBS and penicillin/streptomycin (Invitrogen).

To establish a primary culture of mouse ovarian surface epithelial cells (mOSE), we harvested the ovaries from female mice of about 10 weeks of age and the mOSE cells were dissociated from the ovarian surface after incubating with 0.25% trypsin-EDTA at 37°C for 30 minutes followed by gentle agitation. The mOSE cells were washed and plated in Dulbecco's modified Eagle's medium-F12 media (10% Fetal bovine serum, 5% insulin-transferrin-selenium-A and 5% penicillin streptomycin) in a culture dish. Fresh media was replaced every 2-3 days and the cells were harvested at subconfluence for experimental purposes.

Generation of binding isotherm of NAC1/N130/Profilin-1 and actin

The construction of the binding isotherm was carried out (20) with actin at fixed low concentrations in supernatant, and using increasing amounts of NAC1 immobilized on anti-V5 beads to overcome the limited solubility of NAC1 in aqueous condition. The amount of actin in solution was quantified by high resolution scanning and processing by band densitometric analysis using the BioRad ChemiDoc XRS QuantityOne software in comparison to a standard curve based on actin input and silver staining.
Cell lines and culture conditions

The cell lines used in this study, including SKOV3, HeLa, MCF7, TOV21G and HEK293T, were purchased from ATCC (Rockville, MD, USA), authenticated with short tandem repeat (STR) based genotyping by the Fragment Analysis Facility at the Johns Hopkins University, and matched to their profiles at the ATCC STR profile database for human cell lines. Transfection was performed using the Lipofectamine-2000 reagent (Invitrogen). Nocodazole (100 ng/ml) was used to synchronize the cells at the mitotic phase. Nuclear and cytoplasmic purification of the lysates was carried out as described using the hypotonic swelling method; the purity of the nuclei were verified by microscopy (21).

Recombinant protein production

The NAC1-V5 construct was cloned into the pQE bacterial expression vector for recombinant protein production and purification using Ni-NTA beads (Qiagen). The insoluble protein was refolded using the Pierce protein refolding kit buffer 3 (Pierce) and immobilized on anti-V5 agarose beads (Sigma). Purified recombinant actin and profilin-1 were purchased from Cytoskeleton Inc. (Denver, CO).
Results

NAC1 inactivation or silencing causes a multinucleation phenotype in cancer cells

In order to document the biological roles of NAC1 during cancer cell division, we used two independent and complementary approaches. First, we ectopically expressed a truncated NAC1 construct, N130, in SKOV3 human ovarian cancer cells and HeLa cells to competitively inhibit the functional activity of wild type NAC1. The N130 construct encodes exclusively the BTB domain, which is the minimal motif required for the homodimerization of NAC1; expression of N130 has been shown to competitively disrupt NAC1 homodimerization (7). Following induction of N130 expression in SKOV3, an accumulation of polyploid cells at 4n was observed at 48 hours. After 72 hours, another distinct population of polyploid cells at 8n was detected (Fig. 1A). By direct visualization using immunofluorescence staining, we found that the increase in DNA content corresponded to the increase in the number of multinucleated cells (Fig. 1B). The induction of the BTB domain in HeLa cells caused a similar multinucleation phenotype (Supplementary Fig. S1A and S1B). The multinucleation induced by N130 induction was also accompanied by a significant reduction in cellular proliferation in SKOV3 cells (Fig. 1C).

To control for potential non-specific effects related to N130 expression, we ectopically expressed N130mut in SKOV3 cells. N130mut is a mutant form of N130 containing multiple introduced point mutations that prevent it from forming dimers with full length NAC1 (9). The results demonstrated that, as compared to the wild type N130, the expression of N130mut neither caused a significant reduction in cellular proliferation (Fig.
1D) nor induced multinucleation. We also performed RNAi to determine the specificity of N130-induced phenotypes. NAC1 expression was silenced using lentiviral shRNAs (Supplementary Fig. S2A), and like the effects of N130 induction, silencing of NAC1 in SKOV3 and HeLa cells caused multinucleation in cancer cells (SKOV3: Fig. 1E; HeLa: Supplementary Fig. S2B, S2C). We also found that shRNAs targeting NAC1 suppressed cellular proliferation in SKOV3, HeLa, and MCF7 cancer cells (Supplementary Fig. S2D), all of which express abundant NAC1 (Supplementary Fig. S2E), whereas NAC1 shRNA expression in the TOV21G tumor cell line, which has undetectable NAC1 expression (10), had a less conspicuous effect.

The multinucleation phenotype of cancer cells is caused by abscission failure during cytokinesis

Next, we applied time-lapse microscopy to observe the formation of multinucleation in NAC1-inactivated (N130-induced) cancer cells. As shown in the Supplemental videos, NAC1-inactivated cells (with N130-induction, Video S1) and control cells (without N130-induction, Video S2) underwent normal mitosis and displayed equatorial furrowing. However, in the later phases of cell division, NAC1-inactivated cells were characterized by incomplete constriction and abscission of the contractile ring, and as a result, many of the dividing cells became multinucleated (Video S1). This finding was recapitulated in time-lapse videos of dividing SKOV3 and HeLa cells after treatment with lentiviral NAC1 shRNAs (HeLa: Supplementary Fig. S3; SKOV3: data not shown). Whereas cells treated with control shRNA (Supplementary Fig. S3A) completed cytokinesis and formed two distinct daughter cells, NAC1 shRNA treated cells failed to
complete the final stage of cytokinesis and became multinucleated (Supplementary Fig. S3B).

**Failure of abscission during cytokinesis of cancer cells is a consequence of a loss in traction of dividing cells, impeded constriction of their contractile rings, and reduced migration potential**

We hypothesize that the defect in late cytokinesis was a result of insufficient traction of the dividing cells to facilitate cellular division. To determine the traction generated by dividing cells, we used traction force microscopy to correlate the traction generated by dividing cells with the displacement of fluorescent beads embedded directly beneath the cells in a polyacrylamide substrate. Analysis of the displacement of each bead from its original location during the course of cell division revealed a significant decrease in the maximal displacement of beads by SKOV3 cells after NAC1 inactivation (Fig. 2A), suggesting that NAC1 proteins were important for the generation of traction in the dividing cancer cells. Using immunofluorescence microscopy to visualize actin structures, we compared the size of contractile rings between dividing N130-induced and non-induced cells. Although N130-induced cells correctly positioned the cleavage furrows and contractile rings, these cells displayed a larger average diameter of contractile rings than their non-induced counterparts, suggesting that the constriction of contractile rings was compromised in N130-induced cells (image: Fig. 2B, quantification: Fig. 2C). To determine if there was a loss in migration potential of the cells after silencing of NAC1 (Day 3 and Day 6), live-cell imaging was used to follow the cell displacement trajectories during an overnight observation. After Day 3 and Day 6 under
control shRNA and NAC1 shRNA treatment, typical trajectories (Red, yellow, green, blue) of SKOV3 and HeLa individual cells were plotted by their $x$ and $y$ coordinates (Fig. 3 and Supplementary Fig. S4) and revealed that the silencing of NAC1 caused SKOV3 and HeLa cells to undergo restricted migration and greatly reduced displacement from their original location. As early as three days after NAC1 silencing, both SKOV3 and HeLa cells demonstrated restricted migration and reduced displacement from origin (Fig. 3A and Supplementary Fig. S4A). The silencing of NAC1 was sustained for as long as 6 days after shRNA treatment (Supplementary Fig. S4C). We demonstrated that the reduction in migration and displacement of NAC1 silenced cells was also observed at Day 6 of shRNA treatment in SKOV3 and HeLa cells (Fig. 3B and Supplementary Fig. S4B).

**Expression of NAC1 partially rescues normal cytokinesis in Nac1-null cells**

To determine if NAC1 was essential for effective cytokinesis, we re-introduced NAC1 expression in Nac1-null cells to determine whether ectopic NAC1 would prevent the multinucleated phenotype. For this purpose, we utilized a Nac1 homozygous knockout (Nac1−/−) mouse in which both copies of the BTB domain of the mouse Nacc1 gene were deleted (Fig. 4A). In addition, we bred Nac1 hemizygous knockout mice (Nac1+/−), and the cells isolated from those mice were analyzed in parallel. Western blot analysis demonstrated that Nac1−/− lung fibroblasts did not express a detectable level of Nac1 protein while lung fibroblasts from the Nac1+/− mice expressed detectable, albeit much less, Nac1 compared to cells isolated from wild type Nac1+/+ mice (Fig. 4B). More importantly, we observed that the percentage of multinucleated cells (2.7%) in Nac1+/−
(n= 930) was much lower than in Nac1⁻/⁻ cells (23.7%) (n=1011), while heterozygous Nac1 cells (Nac1⁺/-) (n= 1040) demonstrated an intermediate percentage (12.7%) of multinucleated cells (Fig. 4C and 4D).

To determine if the re-expression of Nac1 protein could rescue the multinucleation phenotype, NAC1 was re-introduced into Nac1⁻/⁻ cells as a V5-NAC1 protein by a retroviral vector. We then quantified the number of multinucleated cells in cultures that were either treated with control virus (n=329) or with the NAC1 expression construct virus (n=304). We found that there was a significant reduction (28.3% to 6.25%) in the percentage of multinucleated cells after the introduction of the NAC1 expression vector (Fig. 4E). The successful introduction of NAC1 expression was confirmed by immunofluorescence detection of the V5 epitope (Fig. 4F) and by Western blot (Fig. 4G). A similar result could be obtained in mouse ovarian surface epithelial (mOSE) cells generated from the same strain of mice (Supplementary Fig. S5).

**Cancer cells after profilin-1 silencing exhibit a similar multinucleation phenotype**

The multinucleation phenotype observed in NAC1 inactivated or silenced cells is reminiscent of multinucleation reported in mouse chondrocytes after silencing of profilin-1 (19). In the current study, by silencing profilin-1 expression (Supplementary Fig. S6A), we were able to demonstrate the formation of multinucleated cells in SKOV3 cells (Fig. 5A) and HeLa cells (Supplementary Fig. S6B and S6C). The silencing of profilin-1 also caused a reduction in cellular proliferation in our previously examined panel of cancer cell lines, MCF7, HeLa, SKOV3 and TOV21G (Supplementary Fig. S6D). Profilin-1 is a
ubiquitous actin monomer binding protein that is known to regulate actin polymerization during cytokinesis (22-24). The similarity of the phenotype observed in chondrocytes and tumor cells after profilin-1 silencing prompted us to investigate the possibility that NAC1 has a biological role in cytokinesis involving profilin-1/actin complexes. Given that the known role of NAC1 involved transcription regulation, it is possible that the multinucleated phenotype induced by NAC1 knockdown was mediated by down-regulation of profilin-1 expression. To test this possibility, we employed Western blot analysis but did not observe significant changes in the levels of profilin-1 protein expression between cells treated with NAC1 shRNA and control shRNA (Supplementary Fig. S2A: right panel), suggesting that the phenotype generated by the knockdown of NAC1 was not due to reduced profilin-1 levels.

Next, using immunofluorescence microscopy we found that NAC1 and profilin-1 co-localized during cell division in HeLa cells (Fig. 5B). Nuclear and cytoplasmic protein extracts from HeLa and MCF7 cells were used for Western blot analysis to analyze the distribution of the proteins in the cellular compartments. Interestingly, NAC1 was mainly found in the nuclear extract during interphase, with low levels in the cytoplasm, while profilin-1 was almost exclusively detected in the cytoplasmic extract (Fig. 5C). When we mitotically arrested cells with the microtubule-depolymerizing drug, nocodazole, and examined NAC1 levels by Western blot in the cytoplasmic fraction, we found that there was a significant amount of NAC1 in the cytoplasmic fraction as compared to the chromosomal fraction (Supplementary Fig. S6E). This cell cycle dependent localization of NAC1 was previously described in an earlier publication (18). Thus, during cell
division NAC1 abundantly accumulated in the cytoplasm where it may colocalize with profilin-1.

Accordingly, co-immunoprecipitation experiments were conducted to determine whether NAC1 and profilin-1 interacted in vivo. We found that endogenous NAC1 and profilin-1 could be co-immunoprecipitated from lysates prepared from HeLa and MCF7 cells (Fig. 5D). Both HeLa and MCF7 cells have abundant NAC1 expression as previously documented (Supplementary Fig. S2E). Reciprocal co-immunoprecipitation experiments using anti-profilin-1 for pull-down and anti-NAC1 for Western blot detection confirmed that NAC1 and profilin-1 were constituents of the same protein complexes.

NAC1 interacts directly with actin monomers

As profilin-1 is an actin binding protein and plays a pivotal role in actin polymerization (23), we investigated the possibility that NAC1 also interacted with actin. Co-immunoprecipitation experiments using cytoplasmic extracts of MCF7 cells demonstrated that NAC1 co-immunoprecipitated with actin monomers in cytoplasmic but not in nuclear lysates (Fig. 6A). To further determine if the NAC1-actin interaction was direct or depended on profilin-1, we performed an in vitro binding assay using NAC1-V5, profilin-1, and actin recombinant proteins. After incubating NAC1-V5 and actin, we observed that actin could be co-eluted with NAC1 on anti-V5 agarose beads. In the absence of NAC1-V5 protein, however, actin was not retained on the anti-V5 beads and was undetectable in the eluted protein fraction (Fig. 6B). We also conducted quantitative binding assays using a method previously described (20) to characterize the protein
interactions (actin standard curve documented in Supplementary Fig. S7A). A fixed amount of actin or profilin-1 protein was incubated with increasing amounts of NAC1-V5-beads. After incubation, the amount of unbound actin or profilin-1 in the supernatant was measured and used to determine the bound fraction. We found that recombinant NAC1 was unable to demonstrate a dose-dependent co-binding of profilin-1 in the binding affinity assay (Supplementary Fig. S7B). On the other hand, we were able to demonstrate the dose-dependent binding of NAC1 and actin in the binding affinity assay (Fig. 6C). Taken together, these results indicated a direct protein-protein interaction between NAC1 and actin, but not between NAC1 and profilin-1, although in vivo co-immunoprecipitation reactions (Fig. 5D) demonstrated NAC1 and profilin-1 are in the same protein complexes.

The quantitative binding assays performed found that NAC1-V5 and actin interacted with a K_d of 0.78 μM (Fig. 6C). As a negative control, an irrelevant protein of similar molecular weight as NAC1, Notch3-ICD-V5 was analyzed in parallel to demonstrate the assay specificity (Supplementary Fig. S7C). To determine the domain of the NAC1 protein that was involved in the direct interaction with actin, we generated another recombinant NAC1 protein composed of only the BTB domain (N130-V5). We carried out a similar quantitative binding assay between N130-V5 and actin. These proteins bound with a K_d of 0.52 μM (Fig. 6D). To further support the finding that the BTB domain of NAC1 was responsible for its interaction with the actin, we used a series of NAC1 deletion mutants (Supplementary Fig. S8A), and were able to confirm that the BTB domain of NAC1 (Supplementary Fig. S8C1) was responsible for its interaction
with the profilin-1/actin complex.

**NAC1 is able to modulate binding between profilin-1 and actin monomers**

Because the interaction between actin and profilin-1 is known to be critical for cytokinesis (22), our results suggested that the interaction between NAC1 and actin could modulate the binding between profilin-1 and actin. We employed Nac1⁻/⁻ lung fibroblasts as a cellular system to test this hypothesis. Due to the relatively high binding affinity between actin and profilin-1, we created a profilin-1 mutant,PFN1⁰⁶⁰A, which has been demonstrated to exhibit reduced actin binding activity (25). We also generated PFN1⁰⁸⁹L, a control that does not affect the binding between profilin-1 and actin (26) (Fig. 7A). As verified by our protein co-immunoprecipitation experiments, PFN1⁰⁶⁰A exhibited diminished binding to actin while mutant PFN1⁰⁸⁹L did not (Fig. 7B). We expressed wild type and mutant profilin-1 in Nac1⁻/⁻ lung fibroblasts previously transfected with a NAC1-V5 expression vector or an empty vector. We observed that in the presence of NAC1-V5, the actin binding activity of profilin-1 decreased, particularly for PFN1⁰⁶⁰A in which actin-binding activity was totally abrogated (Fig. 7C: right panel). Conversely, in fibroblasts without NAC1 expression, PFN1⁰⁶⁰A mutant co-immunoprecipitated with actin (Fig. 7C: left panel), suggesting that the presence of NAC1 inhibited the interaction between profilin-1 and actin.
Discussion

The results from the current study unveil a novel mechanism by which cancer cells facilitate their incessant cellular divisions, which is the cardinal feature of neoplastic diseases. Our results indicate that abundant NAC1 proteins in cancer cells promote cytokinesis through modulating the interaction of actin and profilin-1, ensuring an effective completion of cellular division in highly proliferative tumors. The observation that NAC1 overexpressing tumor cells develop molecular dependence on NAC1 protein (7-9) promises future exploitation by targeting NAC1 as a cytostatic cancer therapy aimed at compromising cytokinesis in cancer cells.

Cytokinesis is a highly complex event involving a cascade of sequential and highly coordinated molecular processes (27). In eukaryotic cells, this is made possible by chromosomal segregation and Rho GTPase signaling followed by the effective assembly and constriction of contractile rings by non-muscle myosin II, actin, and its binding partners before actual cellular division occurs (27-29). For example, disruption of Rho GTPase signaling, which is known to regulate the actin cytoskeleton, can result in the misalignment of the cleavage furrow and contractile ring (30). Cytokinesis failure can also result from the slow ring closure of the contractile apparatus due to inadequate constriction, leading to a cytoplasmic connection between daughter cells that precedes furrow regression (31). As shown in this study, inactivation or silencing of NAC1 did not cause detectable aberrations in early cytokinetic events such as chromosome separation or formation and positioning of cleavage furrow and contractile ring; however, NAC1 inactivation or silencing resulted in the inability of the dividing cells to generate the force required to constrict the contractile actomyosin ring or to generate sufficient traction to
move the dividing cells apart to make the “final cut”, impeding abscission and resulting in incomplete partitioning of the cytoplasm of the cell (29). This finding is consistent with previous studies demonstrating that traction force is required for complete cytokinesis in dividing cells in Dictyostelium and mouse chondrocytes (19, 27).

The actin binding property of NAC1 and its ability to modulate the interaction between profilin-1 and actin may account for the defective cytokinesis observed in tumor cells after NAC1 inactivation or knockdown. Since actin structures have been shown to be important for the regulation of cell shape and movement (Pollard and Cooper, 2009), the demonstration that NAC1 is an actin binding protein could also explain previously reported findings that reducing NAC1 expression by RNA interference decreased cellular motility (10, 32). Apropos to these observations, it has been well established that profilin-1, which is a ubiquitous actin monomer-binding protein, regulates actin polymerization in response to various extracellular signals by catalyzing ADP-to-ATP exchange on G-actin and escorting actin monomers to the growing barbed ends of actin filaments (23, 24). Profilin-1 has been thought to be a key component of the core cytokinesis machinery (19, 22, 33). The fact that NAC1 and profilin-1 co-exist in the same actin complex and that the same phenotype, i.e., incomplete cytokinesis followed by multinucleation, is produced by knockdown of either gene argues that NAC1 plays a role similar to profilin-1 in regulating actin polymerization. Although NAC1 may finely tune the function of profilin-1 in regulating actin dynamics, it remains unclear how NAC1 directly affects actin assembly independent of profilin-1.

Our results demonstrate that NAC1 represents a rate-limiting factor in cytokinesis in cancer cells; that NAC1 gene amplification and upregulation provides tumor cells with
a sufficient amount of NAC1 for sustaining numerous cytokinesis events, but results in the development of molecular dependence on NAC1. Thus, inactivation or knockdown of NAC1 would not allow completion of cytokinesis in those cancer cells. This indicates the possibility of targeting NAC1 in cancer cells for maintenance cancer therapy. This is important because the conventional cytotoxic chemotherapy is always complicated by its cytotoxic effects on normal cells Unlike conventional cytotoxic drugs, NAC1-targeted anti-tumor strategies involving pharmacological compounds that disrupt protein-protein interactions between the well-characterized BTB domains of NAC1 (34) and actin are likely to have minimal cytotoxicity for normal cells because NAC1 is preferentially overexpressed only in cancer cells.

This finding is of great interest in light of the lack of actin-targeting agents in the arsenal of anti-cancer drugs, a consequence of the fact that the known reagents target the actin assembly in both cancer and normal cells (35). That disrupting NAC1 BTB domain protein interactions as a cancer chemotherapeutic strategy is feasible is suggested by the use of peptidomimetic and small molecule inhibitors to disrupt the BTB interacting domain of BCL6, which has been shown to be effective in suppressing tumor growth in B cell lymphomas (36-38). Triggering cytokinesis failure in cancer cells could give rise to either chromosomal instability or apoptosis. However, it is expected that in the presence of the functional p53, cells that were treated with drugs blocking cytokinesis will acquire extreme polyploidy and undergo rapid cell death or senescence (31, 39).

In summary, our findings provide cogent evidence that NAC1 is a member of the actin-binding protein family. The potential involvement of NAC1 in regulating actin organization during late stage cytokinesis represents a functional property well beyond its
canonical function as a transcriptional regulator. By highlighting the participation of NAC1 in regulation of the actin assembly in cancer cells, our results should have profound implications on the study of actin biology in cancer, and should advance our basic understanding of the process of cytokinesis.

Acknowledgements

The authors would like to acknowledge Bin Guan, Alexander Stoeck, Xu Chen, and Pei-Hsun Wu for helpful discussions.

Grant support

This study was supported by an NIH/NCI grants RO1CA103937, RO1CA129080, RO1CA148826, and U54CA143868.

Author contributions

K.L.Y conceived experiments, analyzed data and co-wrote the manuscript. S.F. developed biophysical methods of analysis. M.M.T. initiated protein interaction studies for screening candidate genes. N.J. and K.N. built initial constructs and validated them in vitro. J.W. contributed the Nac1 knockout mouse. D.W. co-supervised the project. T.L.W and I.M.S co-supervised the project and co-wrote the manuscript.
References

Figure Legends

Figure 1. NAC1 inactivation or knockdown in ovarian cancer cells causes a multinucleation phenotype.

A. Flow cytometric analysis shows that induced expression of a NAC1 deletion mutant (N130) containing the BTB domain after 48 hours in SKOV3 cells causes an accumulation of polyploid cells at 4n. After 72 hours, another distinct population of polyploid cells at 8n can be observed. B. Immunofluorescence microscopy demonstrates polyploid cells with two nuclei, which accounts for the doubling of DNA content in SKOV3 cells at 48 hours. Specimens were counterstained with DAPI for the nucleus. Top set: Scale bar, 50 μM. Bottom set: Images obtained using confocal microscope and 40x objective. Scale bar, 25 μM. C. Induction of N130 (BTB domain only) results in growth suppression. D. Induction of N130mut fails to reduce cellular proliferation. E. Silencing of NAC1 by lentiviral shRNA in SKOV3 cells leads to a multinucleated phenotype. Scale bar, 50 μM.

Figure 2. Biophysical effects of NAC1 inactivation or silencing include loss of cellular traction during division, impeded constriction of contractile ring, and reduced displacement from origin over time.

A. Traction force microscopy shows a significant reduction in cellular traction during cytokinesis when N130 (BTB domain only) was induced. A total of 80 beads were tracked in the experiment. ***p< 0.0001 using one-way ANOVA test. Inset: A representative cell undergoing mitosis on collagen-coated bis-polyacrylamide substrate with red fluorescent beads embedded underneath and tracked beads denoted by colored
cross hairs. B. Immunofluorescence staining of actin structures in non-induced vs.
induced SKOV3 N130 tTA cells enabling evaluation of the contractile ring diameter.
Scale bar, 50 μM. C. Induction of N130 (BTB domain only) results in a reduction of
average contractile ring diameter as compared to the non-induced SKOV3 cells during
cell division. The contractile ring diameters of dividing cells between the two conditions
(n=20 each) were measured. Error bars denote standard deviation. ***p<0.0001 using
unpaired t-test.

**Figure 3. Reduced migration and displacement of SKOV3 cells after NAC1
silencing.**

Typical trajectories of individual SKOV3 cells after control lentiviral shRNA and NAC1
shRNA treatment after A. Day 3 and B. Day 6 denoted by red, yellow, green and blue
tracks. Each color denotes the trajectory of a single cell.

**Figure 4. Expression of NAC1 partially rescues multinucleation in Nac1−/− cells.**
A. DNA gel electrophoresis validates the two knockout alleles (440bp) in Nac1−/− mice
and one knockout and one wild type allele (480bp) in Nac1+/− mice. B. Western blot
analysis shows differential protein expression levels of NAC1 in lung fibroblasts isolated
from the respective genotypes. C. Immunofluorescence staining of alpha-tubulin
facilitates the quantification of cells exhibiting multinucleation. Cells were counterstained
with DAPI to reveal nuclei. Arrowheads indicate multinucleated cells. Scale bar, 50 μM.
D. Number of multinucleated cells was presented as a percentage in primary lung
fibroblast cultures established from different Nac1 genotype mice. There is a significant
difference in the proportion of multinucleated cells between different Nac1 genotypes
(**p< 0.0001, Chi-square contingency table). E. NAC1 was ectopically expressed in
Nac1-/- cells, and its expression was associated with a significant decrease in the
percentage of multinucleated cells as compared to control virus-treated group (**p<
0.0001, Chi-square contingency table). F. Double immunofluorescence staining of alpha-
tubulin and V5 (to detect NAC1-V5) facilitates the quantification of cells exhibiting
multinucleation after expression of NAC1. Cells were counterstained with DAPI to reveal
nuclei. Arrowheads denote multinucleated cells. Scale bar, 50 μM. G. Western blot
verified the expression of NAC1-V5 after viral transduction.

Figure 5. Silencing of profilin-1 causes a similar multinucleation phenotype, while
NAC1 and profilin-1 can be isolated in a single protein complex.
A. Silencing of profilin-1 using lentiviral shRNA causes a similar multinucleation
phenotype as NAC1 silencing in SKOV3 cells. Cells were counterstained with DAPI.
Scale bar, 50 μM. B. NAC1 and profilin-1 co-localize in the same cellular compartment
during cell division. Images were obtained using confocal microscopy. Scale bar, 10 μM.
C. Western blot analysis of proteins localized in nuclear and cytoplasmic compartments
of interphase cells (data are from unsynchronized cells). D. Reciprocal protein co-
immunoprecipitation experiments showed that NAC1 complexed with profilin-1 in HeLa
and MCF7 cells expressing abundant NAC1. *asterisk denotes lysates that were
transfected with the profilin-1-GST expression construct.
Figure 6. NAC1 directly binds to actin monomers.

A. NAC1 co-immunoprecipitates with actin monomers in cytoplasmic extract (C) but not in nuclear extract (N) prepared from MCF7 cells. IP, immunoprecipitation; WB, Western blot. Ab, antibody. B. Recombinant protein co-immunoprecipitation confirmed that NAC1 and actin interactions are direct. Recombinant actin co-immunoprecipitated with NAC1-V5 that was immobilized on anti-V5 agarose beads. Actin protein was unable to be retained in the co-immunoprecipitation reaction in the absence of NAC1-V5. C. Analysis of NAC1-V5, and D. analysis of N130-V5 and actin binding affinity using a quantitative anti-V5 pull-down assay. NAC1-V5 and N130-V5 bound to actin in a saturable dose-dependent manner, Kd ~0.78 μM and ~0.52 μM, respectively. Scatchard plots of the binding isotherms were derived.

Figure 7. Protein interactions between profilin-1 and actin can be modulated by the presence of NAC1.

A. Mutant profilin-1 was generated with amino acid changes denoted by asterisk* and the annotated replacement amino acids. B. HEK293T cells were transfected with NAC1-V5 and profilin-1-GST constructs, and the lysates were collected for immunoprecipitation of the GST proteins and immunoblotted for either NAC1 or actin. PFN1Y60A mutant significantly reduces the binding of profilin-1 to actin. C. Interaction of profilin-1 and actin could be modulated by the presence of NAC1. Nac1+/− lung fibroblast cells were cotransfected with the profilin-1-GST constructs in the presence or absence of the NAC1 expression plasmid. Cell lysates were immunoprecipitated for the profilin-1-GST proteins using glutathione-agarose beads and immunoblotted with an anti-actin antibody. Presence
of NAC1 protein reduces the binding of profilin-1 and actin, especially for PFN1$^{Y60A}$ mutant where actin binding is almost completely abrogated.
Figure 1 (Shih)

A. Non-induced, 24hrs induction, 48hrs induction, 72hrs induction

B. Non-induced, Induced (48hrs)

C. SKOV3 N130 tTA

D. SKOV3 N130 mutant

E. control virus, NAC1 shRNA1, NAC1 shRNA2
Figure 2 (Shih)

A

<table>
<thead>
<tr>
<th>bead displacement from origin (μm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
</tr>
<tr>
<td>30</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-induced</th>
<th>Induced (24hrs)</th>
<th>Induced (48hrs)</th>
</tr>
</thead>
</table>

**p<0.0001

B

Non-induced | Induced

Actin DAPI

C

**p<0.0001

Contractile ring diameter (μM)

Non-induced | Induced

SKOV3 N130 tTA
Figure-3 (Shih)

A  Day 3 of knockdown
   SKOV3 control shRNA
   SKOV3 NAC1 shRNA1
   SKOV3 NAC1 shRNA2

B  Day 6 of knockdown
   SKOV3 control shRNA
   SKOV3 NAC1 shRNA1
   SKOV3 NAC1 shRNA2
Wild-Type Mouse
Nac1 +/- Mouse
Nac1 -/- Mouse

Wild-type allele
Knockout allele

***p<0.0001 using Chi-square contingency table

Wild-type Nac1 +/- Nac1 -/-

pWZL control virus
pWZL NAC1-V5 virus

α-tubulin
DAPI

Figure-4 (Shih)

A

480 bp
440 bp

Wild-type allele
Knockout allele

75 kDa
37 kDa

GAPDH

B

C

Wild-type
Nac1 +/-
Nac1 -/-

α-tubulin
DAPI

D

E

Percentage of Cells

Wild Type
Nac1 +/-
Nac1 -/-

Single Nuclei
Multi Nuclei

***p<0.0001 using Chi-square contingency table

Single Nuclei
Multi Nuclei

***p<0.0001 using Chi-square contingency table

F

pWZL control virus
pWZL NAC1-V5 virus

α-tubulin
DAPI

G

Nac1 -/- mOSE

75 kDa
37 kDa

NAC1-V5
GAPDH
Figure 6 (Shih)

A

<table>
<thead>
<tr>
<th>MCF7 lysate</th>
<th>N</th>
<th>C</th>
<th>-</th>
<th>N</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein-G Beads</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>NAC1 Antibody</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

IP Ab: NAC1
WB Ab: Actin

IP Ab: NAC1
WB Ab: NAC1

![Image of gel showing bands for NAC1 and Actin]

B

<table>
<thead>
<tr>
<th>Input only</th>
<th>Wash and elute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-V5 beads</td>
<td>-</td>
</tr>
<tr>
<td>Actin</td>
<td>+</td>
</tr>
<tr>
<td>NAC1-V5</td>
<td>-</td>
</tr>
</tbody>
</table>

NAC1 (75 kDa) ➔
Actin (42 kDa) ➔

![Image of gel showing bands for NAC1 and Actin]

Ponceau S staining

C

**Saturation Binding Data of NAC1-V5 & Actin**

Fractional Actin Complex Bound

NAC1-V5 (µM)

<table>
<thead>
<tr>
<th>0.0</th>
<th>0.5</th>
<th>1.0</th>
<th>1.5</th>
<th>2.0</th>
<th>2.5</th>
<th>3.0</th>
<th>3.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0</td>
<td>0.2</td>
<td>0.4</td>
<td>0.6</td>
<td>0.8</td>
<td>1.0</td>
<td>1.2</td>
<td>1.4</td>
</tr>
</tbody>
</table>

Scatchard Plot

Bound/Free

Bound

Silver Stain

NAC1-V5 input (75 kDa)
Actin in supernatant (42 kDa)
Actin in supernatant (in equi-volume beads) (42 kDa)

D

**Saturation Binding Data of N130-V5 & Actin**

Fractional Actin Complex Bound

N130-V5 (µM)

<table>
<thead>
<tr>
<th>0.0</th>
<th>0.5</th>
<th>1.0</th>
<th>1.5</th>
<th>2.0</th>
<th>2.5</th>
<th>3.0</th>
<th>3.5</th>
<th>4.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0</td>
<td>0.2</td>
<td>0.4</td>
<td>0.6</td>
<td>0.8</td>
<td>1.0</td>
<td>1.2</td>
<td>1.4</td>
<td>1.6</td>
</tr>
</tbody>
</table>

Scatchard Plot

Bound/Free

Bound

Silver Stain

N130-V5 input (18 kDa)
Actin in supernatant (42 kDa)
A

Profilin-1 site-directed mutagenesis

MAGWNAYIDNLMADGTQDAIAVGYKDSPSVWAAVPKTFVNNITPAEVGVLVGVKDRSSFYVNGL
TLGGQKCSVIRDSSLDQGEFSMDLRTKSTGGAPTFTVTVTKTDKTLVLLMGKEGVHGGLINKKC
YEMASHLRSSQY

B

HEK293T co-immunoprecipitation

<table>
<thead>
<tr>
<th>GST pulldown</th>
<th>GST+NAC1-V5</th>
<th>GST+NAC1-V5</th>
<th>GST+NAC1-V5</th>
</tr>
</thead>
<tbody>
<tr>
<td>WB Ab: V5</td>
<td>NAC1-V5 (75kDa)</td>
<td>NAC1-V5</td>
<td>NAC1-V5</td>
</tr>
<tr>
<td>Actin</td>
<td>Actin (42kDa)</td>
<td>Actin</td>
<td>Actin</td>
</tr>
<tr>
<td>Input lysate</td>
<td>WB Ab: V5</td>
<td>NAC1-V5 (75kDa)</td>
<td>NAC1-V5</td>
</tr>
<tr>
<td>WB Ab: Actin</td>
<td>Actin (42kDa)</td>
<td>Actin</td>
<td>Actin</td>
</tr>
<tr>
<td>GST</td>
<td>PFN1-GST (26kDa)</td>
<td>PFN1-GST</td>
<td>PFN1-GST</td>
</tr>
<tr>
<td>GST</td>
<td>GST (26kDa)</td>
<td>GST</td>
<td>GST</td>
</tr>
</tbody>
</table>

C

Nac1 -/- lung fibroblast

<table>
<thead>
<tr>
<th>GST pulldown</th>
<th>GST</th>
<th>PFN1-GST</th>
<th>PFN1&lt;sub&gt;Y60A&lt;/sub&gt;-GST</th>
<th>PFN1&lt;sub&gt;R89L&lt;/sub&gt;-GST</th>
</tr>
</thead>
<tbody>
<tr>
<td>WB Ab: Actin</td>
<td>Actin (42 kDa)</td>
<td>Actin (42 kDa)</td>
<td>Actin (42 kDa)</td>
<td>Actin (42 kDa)</td>
</tr>
</tbody>
</table>

Nac1 -/- transfected with NAC1-V5

<table>
<thead>
<tr>
<th>GST pulldown</th>
<th>GST</th>
<th>PFN1-GST</th>
<th>PFN1&lt;sub&gt;Y60A&lt;/sub&gt;-GST</th>
<th>PFN1&lt;sub&gt;R89L&lt;/sub&gt;-GST</th>
</tr>
</thead>
<tbody>
<tr>
<td>WB Ab: Actin</td>
<td>Actin (42 kDa)</td>
<td>Actin (42 kDa)</td>
<td>Actin (42 kDa)</td>
<td>Actin (42 kDa)</td>
</tr>
<tr>
<td>WB Ab: GST</td>
<td>PFN1-GST (41 kDa)</td>
<td>GST (26kDa)</td>
<td>GST (26kDa)</td>
<td></td>
</tr>
<tr>
<td>WB Ab: V5</td>
<td>NAC1-V5 (75 kDa)</td>
<td>GST (26kDa)</td>
<td>GST (26kDa)</td>
<td></td>
</tr>
</tbody>
</table>
NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells

Kai Lee Yap, Stephanie I. Fraley, Michelle M. Thiaville, et al.

Cancer Res  Published OnlineFirst July 3, 2012.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-12-0302

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2012/07/10/0008-5472.CAN-12-0302.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.